Novartis CEO Joins Anthropic Board as AI Firm Pushes Into Healthcare

Anthropic announced that Vas Narasimhan, CEO of pharmaceutical company Novartis, is joining its board of directors. The move signals Anthropic's strategic pivot toward healthcare and life sciences applications. This comes weeks after Anthropic acquired biotech startup Coefficient Bio for approximately $400 million, underscoring a deliberate expansion into the pharmaceutical and biotech sectors.
Anthropic announced that Vas Narasimhan, CEO of pharmaceutical company Novartis, is joining its board of directors. The move signals Anthropic's strategic pivot toward healthcare and life sciences applications. This comes weeks after Anthropic acquired biotech startup Coefficient Bio for approximately $400 million, underscoring a deliberate expansion into the pharmaceutical and biotech sectors.
- Novartis CEO Vas Narasimhan joins Anthropic's board
- Board addition reflects Anthropic's growing focus on healthcare and life sciences
- Follows Anthropic's $400 million acquisition of biotech startup Coefficient Bio earlier this month
- Signals strategic positioning of Claude AI for pharmaceutical and biotech applications
Anthropic is making a deliberate institutional push into healthcare, a sector with high regulatory requirements and significant AI application potential. The combination of a major pharma CEO on the board and a biotech acquisition suggests Anthropic sees healthcare as a core vertical for Claude, not a peripheral use case.
- Anthropic is diversifying revenue and application focus beyond consumer and enterprise software into regulated industries
- Novartis gains early access to Claude capabilities tailored for pharmaceutical research, drug discovery, and regulatory workflows
- The board appointment legitimizes Anthropic's healthcare ambitions and may accelerate adoption among other large pharma companies
Our Briefing
Weekly signal. No noise. Built for founders, operators, and AI-curious professionals.
No spam. Unsubscribe any time.



